Joseph Gligorov
AuthID: R-00F-ESZ
1
TÃTULO: Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
AUTORES: Aapro, Matti; Cardoso, Fatima; Curigliano, Giuseppe; Eniu, Alexandru; Gligorov, Joseph; Harbeck, Nadia; Mueller, Andreas; Pagani, Olivia; Paluch Shimon, Shani; Senkus, Elzbieta; Thurlimann, Beat; Zaman, Khalil;
PUBLICAÇÃO: 2022, FONTE: BREAST, VOLUME: 66
AUTORES: Aapro, Matti; Cardoso, Fatima; Curigliano, Giuseppe; Eniu, Alexandru; Gligorov, Joseph; Harbeck, Nadia; Mueller, Andreas; Pagani, Olivia; Paluch Shimon, Shani; Senkus, Elzbieta; Thurlimann, Beat; Zaman, Khalil;
PUBLICAÇÃO: 2022, FONTE: BREAST, VOLUME: 66
INDEXADO EM: 
Scopus 
WOS
Scopus WOS2
TÃTULO: Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe Full Text
AUTORES: Vrdoljak, E; Gligorov, J; Wierinck, L; Conte, P; De Greve, J; Meunier, F; Palmieri, C; Travado, L; Walker, A; Wiseman, T; Wuerstlein, R; Alba, E; Biurrun, C; D'Antona, R; Sola Morales, O; Ubaysi, C; Ventura, R; Cardoso, F;
PUBLICAÇÃO: 2021, FONTE: BREAST, VOLUME: 55
AUTORES: Vrdoljak, E; Gligorov, J; Wierinck, L; Conte, P; De Greve, J; Meunier, F; Palmieri, C; Travado, L; Walker, A; Wiseman, T; Wuerstlein, R; Alba, E; Biurrun, C; D'Antona, R; Sola Morales, O; Ubaysi, C; Ventura, R; Cardoso, F;
PUBLICAÇÃO: 2021, FONTE: BREAST, VOLUME: 55
INDEXADO EM: Scopus WOS
Scopus WOS3
TÃTULO: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
AUTORES: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9
AUTORES: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9
INDEXADO EM: WOS 
CrossRef
WOS CrossRef4
TÃTULO: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Full Text
AUTORES: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLICAÇÃO: 2014, FONTE: LANCET ONCOLOGY, VOLUME: 15, NÚMERO: 12
AUTORES: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLICAÇÃO: 2014, FONTE: LANCET ONCOLOGY, VOLUME: 15, NÚMERO: 12
